Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer
RADNOR, Pa., April 11, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Lorianne K....
View HTML
Toggle Summary FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder
RADNOR, Pa., June 29, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the U.S....
View HTML
Toggle Summary Ganaxolone and Diazepam Administered Intravenously Synergistically Block Seizures in Animal Model of Status Epilepticus
Data Presented at Neuroscience 2016 RADNOR, Pa., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, presented preclinical data showing...
View HTML
Toggle Summary Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference
RADNOR, Pa., April 10, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, presented Phase 1 clinical data showing the safety and tolerability of...
View HTML
Toggle Summary Ganaxolone Phase 1 Data Supports Progressing to Phase 2 in Patients with Status Epilepticus
Data Presented at the 141 st Annual Meeting of the American Neurological Association RADNOR, Pa., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric...
View HTML
Toggle Summary Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model
Data Published in Neuropharmacology RADNOR, Pa., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the publication of...
View HTML
Toggle Summary Ganaxolone Reduces Seizures in Females with PCDH19 Pediatric Epilepsy
Positive Results from First Ever Proof-of-Concept Clinical Study in Children with the Rare Genetic Mutation of PCDH19...
View HTML
Toggle Summary Marinus Announces Clinical Development Plans for Ganaxolone Intravenous Formulation
Plans to initiate clinical trial in Status Epilepticus Preclinical Models Demonstrate Robust Efficacy in Benzodiazepine-Resistant Status Epilepticus RADNOR, Pa., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development...
View HTML
Toggle Summary Marinus Announces Key Initial Observations From Study in PCDH19 Female Pediatric Epilepsy
Enrollment and Dosing Continues With Full Data Expected in 2016...
View HTML
Toggle Summary Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder
Plans to Apply for Orphan Drug Designation RADNOR, Pa., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), today announced positive preliminary data from the initial CDKL5 patients enrolled in its ongoing Phase 2 open-label study evaluating its CNS-selective GABA A...
View HTML